Literature DB >> 16146636

Inhibition of Shc/Grb2 protein-protein interaction suppresses growth of B104-1-1 tumors xenografted in nude mice.

Hyae-Kyeong Kim1, Moon-Jin Jeong, Mi-Young Kong, Mi Young Han, Kwang-Hee Son, Hwan Mook Kim, Su Hyung Hong, Byoung-Mog Kwon.   

Abstract

Actinomycin D was revealed as an inhibitor of Shc/Grb2 interaction in cell lines from our recent study. Shc and Grb2 proteins are important molecules in Ras signaling pathways leading to cellular differentiation and proliferation, which require dramatic morphological changes. It was detected by transmission electron microscopy that actinomycin D induced significant changes in cellular ultrastructures of B104-1-1 cells and confirmed that the changes were due to inhibition of Shc/Grb2 interaction by actinomycin D rather than its inhibitory effect on transcription. Because actinomycin D was dispersed mainly in cytoplasm and Shc peptide (synthetic 13 amino acid tyrosine phosphorylated polypeptide) successfully displaced actinomycin D binding to its cellular targets while the other polypeptide from PDGF receptor could not. We examined the effect of actinomycin D on growth of B104-1-1 tumor xenografted in nude mice. Tumor growth was inhibited in vivo after treatment with this inhibitor. Efficacy was correlated with a reduction in the levels of Shc/Grb2 binding in excised tumors. These results suggest that actinomycin D inhibited Shc/Grb2 interaction in B104-1-1 tumor xenografted in nude mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16146636     DOI: 10.1016/j.lfs.2005.04.067

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Grb2-SH3 ligand inhibits the growth of HER2+ cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel.

Authors:  Brunilde Gril; Michel Vidal; Franck Assayag; Marie-France Poupon; Wang-Qing Liu; Christiane Garbay
Journal:  Int J Cancer       Date:  2007-07-15       Impact factor: 7.396

Review 2.  Grb2 signaling in cell motility and cancer.

Authors:  Alessio Giubellino; Terrence R Burke; Donald P Bottaro
Journal:  Expert Opin Ther Targets       Date:  2008-08       Impact factor: 6.902

3.  p66shc negatively regulates insulin-like growth factor I signal transduction via inhibition of p52shc binding to Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 leading to impaired growth factor receptor-bound protein-2 membrane recruitment.

Authors:  Gang Xi; Xinchun Shen; David R Clemmons
Journal:  Mol Endocrinol       Date:  2008-07-07

4.  Neurodegeneration in Alzheimer disease: role of amyloid precursor protein and presenilin 1 intracellular signaling.

Authors:  Mario Nizzari; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Aldo Pagano; Carola Porcile; Claudio Russo; Tullio Florio
Journal:  J Toxicol       Date:  2012-02-08

5.  CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma.

Authors:  M Teodorczyk; S Kleber; D Wollny; J P Sefrin; B Aykut; A Mateos; P Herhaus; I Sancho-Martinez; O Hill; C Gieffers; J Sykora; W Weichert; C Eisen; A Trumpp; M R Sprick; F Bergmann; T Welsch; A Martin-Villalba
Journal:  Cell Death Differ       Date:  2015-01-23       Impact factor: 15.828

6.  Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity.

Authors:  Hung-Ju Shih; Hsiao-Huei Chen; Yen-An Chen; Meng-Hsun Wu; Gan-Guang Liou; Wei-Wen Chang; Linyi Chen; Lu-Hai Wang; Hsin-Ling Hsu
Journal:  Oncotarget       Date:  2012-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.